GLSI Stock — Greenwich LifeSciences Inc.: Cash, EV, Pipeline

Share price

$18.99

Market cap

$278.7M

Cash

$8.9M

Enterprise value

$269.8M

Balance sheet

Cash	$8.9M
Debt	$0.0M
Net cash	$8.9M
Enterprise value	$269.8M
Basic shares	14.7M shares
Fully diluted shares	17.9M shares
Fully diluted market cap	$340.0M
Cash per share	$0.60

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading GLSI daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	GLSI-100	Phase 3	Breast Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

GLSI-100

Phase 3 · Active Modality: peptide immunotherapy (GP2 peptide + GM-CSF immunoadjuvant)

Aliases GP2 + GM-CSF

Target HER2/neu

Partnerships Henry M. Jackson Foundation (HJF): exclusive license to GP2 (annual maintenance fee, milestones, royalties); rights to Phase II trial data

Indications

HER2/neu-positive breast cancer (operable, node-positive and high-risk node-negative; recurrence prevention) (Phase 3)

Status note Sole clinical program. Phase 3 Flamingo-01 enrolling HER2 1+, 2+ and 3+ (over-expressor) patients; expanding into Europe with up to 150 global sites planned. No dated readout stated in this filing.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	GLSI-100
Lead indication	Breast Cancer
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05232916	Phase 3	Recruiting	Sponsor	GLSI	—	Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Greenwich LifeSciences, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

GLSI — Greenwich LifeSciences Inc.